The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...

Analysts expect scPharmaceuticals to post earnings of ($0.39) per share and revenue of $12.08 million for the quarter. scPharmaceuticals Price Performance Shares of NASDAQ:SCPH opened at $2.93 on ...

Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of scPharmaceuticals in a ...

Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...

The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for Furoscix(furosemide), expanding its indication to include oedema treatment ...

TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) today and set a price target of $25.00.Discover ...

Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient ...

But that doesn't mean long term investors can avoid big losses. To wit, the scPharmaceuticals Inc. (NASDAQ:SCPH) share price managed to fall 68% over five long years. That is extremely sub-optimal, to ...

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing ...